Peptide receptor radionuclide therapy (PRRT) with lutetium dotatate is a treatment for well-differentiated neuroendocrine tumors that the U.S. Food and Drug Administration approved in 2018, but ...
Moderators of Intervention Efficacy in the Pathways to Wellness Trial of Survivorship Education and Mindfulness Meditation for Younger Breast Cancer Survivors Patients with advanced, ...
A simple blood draw can provide physicians with valuable information that can determine if peptide receptor radionuclide therapy (PRRT) is likely to be effective in a patient with neuroendocrine ...
Socioeconomic disparities in access to and outcomes of liver transplantation (LT) for hepatocellular carcinoma (HCC). A phase 2 dose expansion study of ZG006, a trispecific T cell engager targeting ...
The FDA has given tentative approval to the abbreviated new drug application (ANDA) for PNT2003, a radioequivalent version of lutetium Lu 177 dotatate (Lutathera) indicated for treatment of ...
J. Bart Rose, M.D., MAS., an associate professor in the UAB Department of Surgery, joined UAB MedCast to discuss the complexity of neuroendocrine tumors (NETs) and the use of peptide receptor ...
A new type of peptide receptor radionuclide therapy (PRRT) has been shown to control disease in 85 percent of patients with metastatic neuroendocrine neoplasms, achieving complete remission in some ...
Targeted Oral Therapies in Progressive Small Bowel Neuroendocrine Tumor: Everolimus and Cabozantinib
Cabozantinib is presented as an emerging option with activity across extrapancreatic neuroendocrine tumors. Dr Lieu highlights its distinct mechanism of action and discusses how it expands treatment ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results